

# Antiplatelet Therapy for Secondary CVD Prevention

*So Many Choices; What Should We Do?*

## PROGRAM SYLLABUS

Presented by

**SPEAKER NAME, MD**

Hospital Name

Date

Jointly provided by **Potomac Center for Medical Education** and **Rockpointe**

Supported by an independent educational grant from Merck.

**pcme**  
Potomac Center for Medical Education

**Rockpointe**

## CONTENTS

Program Overview/Statement of Need .....	Page 3
Target Audience and Learning Objectives.....	Page 3
CME Statements .....	Page 4
Disclosures .....	Page 5
Steering Committee .....	Pages 6-7
Faculty.....	Page 8

## ADDITIONAL PACKET CONTENTS

Pre-activity Survey.....	Front of packet
<i>After filling out the survey, please separate from packet and return to onsite staff</i>	
Program Slides	
<i>Copy of presentation slides with space for note-taking</i>	
Post-activity Survey and CME Evaluation.....	Back of packet
<i>After filling out the survey and evaluation, please separate from packet and return to onsite staff. The evaluation must be completed to receive CME credit.</i>	

## PROGRAM OVERVIEW/STATEMENT OF NEED

The Potomac Center for Medical Education and Rockpointe welcome you to ***Antiplatelet Therapy for Secondary CVD Prevention: So Many Choices; What Should We Do?***, a CME-certified Grand Rounds program designed to give medical professionals the latest news and information on the management of acute coronary syndrome patients and secondary prevention of recurrence.

Antithrombotic therapy provides secondary prevention of high-risk patients. Considerable residual CVD risk remains, but it is becoming apparent that longer-term therapies can reduce this. In fact, there are now many options for longer-term prevention of CVD recurrences. The question is which antithrombotic therapy should be used to meet the needs of individual patients. There are also a number of unresolved issues involving how/when to switch antithrombotic therapies, the potential role of concomitant therapies, and prospects for secondary prevention in other high-risk populations.

***Antiplatelet Therapy for Secondary CVD Prevention*** will address these vital issues and explore which patients are appropriate candidates for which therapies, and which patients need longer-term antiplatelet therapies for secondary prevention.

## TARGET AUDIENCE

This CME-certified initiative is intended for hospital staff members who specialize in cardiology, interventional cardiology, interventional radiology, and vascular surgery, as well as fellows, residents, and other health care professionals interested in atherosclerotic cardiovascular disease.

## EDUCATIONAL OBJECTIVES

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

*At the conclusion of this activity, participants should be able to demonstrate the ability to:*

- Appraise the clinical data supporting long-term use of antithrombotics in patients with a history of CVD
- Analyze processes of switching therapies or employing concomitant therapies to achieve optimal balance of anti-ischemic protection vs bleeding risk
- Customize longer-term therapies to the needs of particular patients, taking into consideration the evolving landscape of additional indications

## ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

## PHYSICIAN CREDIT DESIGNATION

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 *AMA PRA Category 1 credit<sup>TM</sup>*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## SPECIAL SERVICES



Event staff will be glad to assist you with any special needs.

## FEE AND RECEIVING CME CREDIT

There is no fee for this educational activity. To receive CME credit the participant must:

- Participate in this one-hour-long program in its entirety;
- Sign in / sign out on the sheet provided by the host coordinator;
- Complete the evaluation forms;
- Return the evaluation forms to the host coordinator.

## DISCLOSURE/CONFLICT OF INTEREST STATEMENT

The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

## DISCLOSURES

### *Faculty Speaker*

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

**Faculty Speaker, MD:** *Consultant:* Pharma Name; *Clinical Investigator:* Pharma Name

### *Steering Committee*

The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

**Deepak L. Bhatt, MD, MPH:** *Research:* Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company

**Christopher P. Cannon, MD:** *Research:* Accumetrics, Arisaph, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Merck, Takeda; *Consultant:* Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, Essentialis, GlaxoSmithKline, Kowa, Lipimedix, Merck, Pfizer, Regeneron, Sanofi, Takeda

### *Non-faculty Content Contributors*

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

**Barry Watkins, PhD; Blair St. Amand; Jay Katz, CHCP; Dana Simpler, MD:** Nothing to disclose

## FDA DISCLOSURE

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

## STEERING COMMITTEE



### **DEEPAK L. BHATT, MD, MPH**

Executive Director, Interventional Cardiovascular Programs  
Brigham and Women's Hospital Heart and Vascular Center  
Professor of Medicine, Harvard Medical School  
Boston, MA

**Deepak L. Bhatt, MD, MPH** is Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center and Professor of Medicine at Harvard Medical School. He is also a Senior Physician at Brigham and Women's Hospital and a Senior Investigator in the TIMI Study Group.

After graduating as valedictorian from the Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology, while also serving as a Research Associate at Harvard Medical School. He received his medical doctorate from Cornell University. He completed a Masters in Public Health with a concentration in clinical effectiveness at Harvard University. His internship and residency in internal medicine were performed at the Hospital of the University of Pennsylvania, and his cardiovascular training was at the Cleveland Clinic. He also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention, as well as serving as Chief Interventional Fellow at Cleveland Clinic, where he spent several years as an interventional cardiologist and an Associate Professor of Medicine. He served for many years as Director of the Interventional Cardiology Fellowship and as Associate Director of the Cardiovascular Medicine Fellowship. He also served as Associate Director of the Cleveland Clinic Cardiovascular Coordinating Center. He was then recruited to be the Chief of Cardiology at VA Boston Healthcare System, where he served for several years. Dr. Bhatt has been listed in *Best Doctors in America* from 2005 to 2014.

Dr. Bhatt's research interests include acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He has authored or co-authored more than 600 publications. He is the editor of *Atherothrombosis in Clinical Practice* published by Oxford University Press and of *Peripheral and Cerebrovascular Intervention* published by Springer. He was the international PI for the CHARISMA and CRESCENDO trials and co-PI of the three CHAMPION trials. He served as Chair of COGENT and helped lead STAMPEDE. He serves as Co-chair of the REACH registry and chairs REDUCE-IT. He is co-PI of SAVOR-TIMI 53, SYMPPLICITY HTN-3, and THEMIS. He is the current Chair of the AHA-GWTG Steering Committee. He is Associate Editor for clinical trials for the ACC's *Cardiosource*. Dr. Bhatt has been a visiting lecturer at a number of prestigious institutions throughout the world, and has been interviewed extensively by news agencies on numerous topics. He is the Editor of the peer-reviewed *Journal of Invasive Cardiology*, Chief Medical Editor of *Cardiology Today's Intervention* for healthcare professionals, and Editor-in-Chief of the *Harvard Heart Letter* for patients.

## STEERING COMMITTEE



**CHRISTOPHER P. CANNON, MD**


Executive Director of Cardiometabolic Trials  
Harvard Clinical Research Institute  
Professor of Medicine  
Harvard Medical School  
Senior Physician, Cardiovascular Division  
Brigham and Women's Hospital  
Boston, MA

**Christopher P. Cannon, MD** is a Professor of Medicine at Harvard Medical School, and Senior Physician in the Cardiovascular Division at Brigham and Women's Hospital. He earned his medical doctorate from Columbia University College of Physicians and Surgeons in New York, then completed his internal medicine residency at Columbia Presbyterian Medical Center and his cardiovascular fellowship at Brigham and Women's Hospital.

Dr. Cannon has published more than 1000 original articles, reviews, or electronic publications in the field of acute coronary syndromes and prevention and has authored or edited 17 books. He has received numerous awards, including leadership awards from the American College of Cardiology and the American Heart Association.

As a Senior Investigator of the TIMI Study Group, he has been Principal Investigator of more than 15 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, and the IMPROVE IT trial. Dr. Cannon also serves as Executive Director of Cardiometabolic Trials at the Harvard Clinical Research Institute (HCRI). He is leading the RE-DUAL PCI trial, studying novel anticoagulant strategies in patients with atrial fibrillation undergoing stenting, and collaborates on many other trials and registry projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids, and prevention.

**FACULTY**



**SPEAKER'S NAME, DEGREES**

Title  
Affiliation  
City, STATE

Speaker's biography goes here.